Clinical Trials for Pharmacyclics

Explore 18 clinical trials worldwide

Showing 1-18 of 18 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Pharmacyclics

Clinical Trials (18)

NCT05963074
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
PHASE2Recruiting
320 participants
Started: May 30, 2024 · Completed: Mar 19, 2029
2 conditions2 sponsors74 locations
NCT04450173
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
PHASE2Recruiting
40 participants
Started: Feb 24, 2021 · Completed: Apr 30, 2026
6 conditions4 sponsors4 locations
NCT04273139
Ibrutinib + Venetoclax in Untreated WM
PHASE2Active, not recruiting
45 participants
Started: Jul 9, 2020 · Completed: Feb 1, 2028
2 conditions3 sponsors2 locations
NCT04212013
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
PHASE3Active, not recruiting
23 participants
Started: Dec 23, 2019 · Completed: Mar 18, 2027
1 condition2 sponsors10 locations
NCT03702725
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
PHASE1Active, not recruiting
14 participants
Started: Aug 29, 2019 · Completed: Mar 1, 2026
3 conditions2 sponsors5 locations
NCT03703167
Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)
PHASE1Active, not recruiting
25 participants
Started: Jan 22, 2019 · Completed: Nov 30, 2025
2 conditions2 sponsors7 locations
NCT03646461
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
PHASE2Active, not recruiting
5 participants
Started: Oct 17, 2018 · Completed: Dec 30, 2025
2 conditions2 sponsors1 location
NCT03422393
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
PHASE1Active, not recruiting
24 participants
Started: May 1, 2018 · Completed: Aug 31, 2028
2 conditions2 sponsors1 location
NCT03462719
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
PHASE3Active, not recruiting
211 participants
Started: Apr 17, 2018 · Completed: Apr 5, 2029
1 condition2 sponsors87 locations
NCT03198026
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
PHASE2Active, not recruiting
30 participants
Started: Feb 20, 2018 · Completed: Feb 20, 2032
19 conditions3 sponsors1 location
NCT03379428
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
PHASE1/PHASE2Active, not recruiting
34 participants
Started: Nov 29, 2017 · Completed: Jan 31, 2025
2 conditions3 sponsors1 location
NCT02997761
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
PHASE2Recruiting
20 participants
Started: Jun 27, 2017 · Completed: Sep 30, 2025
2 conditions3 sponsors1 location
NCT03229200
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
PHASE4Enrolling by invitation
600 participants
Started: May 22, 2017 · Completed: May 10, 2027
5 conditions2 sponsors98 locations
NCT02518555
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
PHASE2Active, not recruiting
42 participants
Started: Jan 12, 2016 · Completed: Dec 1, 2025
2 conditions2 sponsors1 location
NCT02315326
Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
PHASE1/PHASE2Recruiting
109 participants
Started: Dec 31, 2014 · Completed: Dec 31, 2026
2 conditions3 sponsors7 locations
NCT02251548
A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
PHASE2Active, not recruiting
85 participants
Started: Oct 31, 2014 · Completed: Jan 31, 2027
2 conditions4 sponsors9 locations
NCT01479842
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
PHASE1Active, not recruiting
48 participants
Started: Mar 26, 2014 · Completed: Mar 1, 2026
10 conditions2 sponsors1 location
NCT01804686
A Long-term Extension Study of PCI-32765 (Ibrutinib)
PHASE3Recruiting
700 participants
Started: Sep 9, 2013 · Completed: Jan 29, 2027
7 conditions2 sponsors174 locations